Business context and reporting period
Universe Pharmaceuticals INC filed this Form 6-K for October 2026 to report results of its September 30, 2026 annual general meeting. This is a corporate-governance filing, not a financial-results report.
Shareholders representing approximately 88.48% of voting rights were present in person or by proxy, and a quorum was established. All proposals were approved.
Key financial metrics
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating and financial performance data.
Material decisions and changes
- Gang Lai, Lin Yang, Jiawen Pang, Ding Zheng, and Yongping Yu were re-elected as directors until the next annual general meeting. Support ranged from 99.183% to 99.908% of votes reported for each proposal.
- Shareholders approved a conditional 1-for-10 consolidation of both Class A and Class B ordinary shares. It is triggered if the Nasdaq closing bid price is below $1.00 for three consecutive trading days within 12 months of the resolution, and is to take effect on the 25th trading day after the trigger event. Fractional shares would be rounded up to the next whole share.
- In connection with the consolidation, authorized share counts would fall from 1.8 billion to 180 million Class A shares and from 200 million to 20 million Class B shares; par value per share would rise from $0.00001 to $0.0001. Authorized share capital remains $20,000.
- Shareholders also approved adoption of an amended and restated memorandum of association, conditional on and immediately following the consolidation, and approved authority to adjourn the meeting if needed for further proxy solicitation or voting.
Outlook, risks, and unusual items
No financial guidance or operating outlook is provided. The approved reverse split is contingent, not reported as completed. Its trigger condition highlights a potential Nasdaq minimum-bid-price compliance concern; the filing does not state whether the condition has occurred.
Important facts for investors to verify
- Whether the share-price trigger occurs and the timing and implementation of any consolidation.
- Nasdaq listing status and any subsequent company announcements concerning bid-price compliance.
- The final share counts and trading arrangements if the consolidation takes effect, including treatment of fractional entitlements.
- The terms of the amended and restated memorandum of association, which the filing says was annexed to the September 1, 2026 proxy statement.